Abstract
Giant cell tumor of bone (GCT) is an aggressive bone tumor consisting of multinucleated osteoclast-like giant cells and proliferating osteoblast-like stromal cells. The signaling mechanism involved in GCT stromal cell osteoblastic differentiation is not fully understood. Previous work in our lab reported that GCT stromal cells express high levels of TWIST1, a master transcription factor in skeletal development, which in turn down-regulates Runx2 expression and prevents terminal osteoblastic differentiation in these cells. The purpose of this study was to determine the upstream regulation of TWIST1 in GCT cells. Using GCT stromal cells obtained from patient specimens, we demonstrated that fibroblast growth factor receptor (FGFR)-2 signaling plays an essential role in bone development and promotes differentiation of immature osteoblastic cells. Fibroblast growth factor (FGF)-2 stimulates FGFR-2 expression, resulting in decreased TWIST1 expression and increased Runx2, alkaline phosphastase (ALP) and osteopontin (OPN) expression. Inhibition of FGFR-2 through siRNA decreased the expression of ALP, Runx2 and OPN in GCT stromal cells. Our study also confirmed that FGF-2 ligand activates downstream ERK1/2 signaling and pharmacological inhibition of the ERK1/2 signaling pathway suppresses FGF-2 stimulated osteogenic differentiation in these cells. Our results indicate a significant role of FGFR-2 signaling in osteoblastic differentiation in GCT stromal cells.
Highlights
Giant cell tumor of bone (GCT) is an aggressive osteolytic and potentially metastatic bone tumor
We have studied the role of FGFR2-IIIc in the regulation of the TWIST1 and Runx2 osteoblastic transcription factors and its activation of the extracellular-signal-regulated kinase 1/2 (ERK1/2) signaling in GCT stromal cells
We have identified a regulatory pathway involving Fibroblast growth factor (FGF)-2 and FGFR2-IIIc, which plays a role in osteogenic differentiation in GCT stromal cells
Summary
Giant cell tumor of bone (GCT) is an aggressive osteolytic and potentially metastatic bone tumor. Cell culture experiments have shown that the preosteoblast-like GCT mesenchymal stromal cells are the only proliferating component of GCT, and are arrested in an immature differentiation state [6,7]. The formation of skeletal elements is controlled by a complex network of signaling molecules that regulate the differentiation of mesenchymal stromal cells into osteoblasts and terminal differentiation into osteocytes under appropriate stimulation by hormones and local factors such as fibroblast growth factors (FGFs) [8,9,10]. FGF signaling plays an essential role in bone development, promoting proliferation of immature osteoblast/osteoprogenitor cells and increasing apoptosis upon exposure of cells to differentiation media [11,12]. Four fibroblast growth factor receptor genes (FGFR1–4) have been identified in mammalian developmental processes
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.